Eight therapies have outgrown the IPM growth
The Indian pharma market (IPM) clocked Rs 7717 crores in May 2015. The market grows at 11 per cent in May 2015. Amongst the top 10, Sun grew by 19.9 per cent followed by Cipla at 15.4 per cent and Abbott at 13.2 per cent. 23 corporate have crossed the growth of IPM for May 2015 amongst top 50.
Amongst the top 50 corporate, Akumentis has the highest growth of 29.1 per cent followed by Glenmark at 28.9 per cent and Torrent at 27 per cent. 25 corporate showed growths more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporate, Glenmark has the highest growth of 28.9 per cent followed by Torrent at 27 per cent and Aristo at 21.7 per cent.
Amongst the 21-30 ranked corporate, MSD has the highest growth at 23.9 per cent per cent followed by Wockhardt 21.2 per cent and Alembic at 15.1 per cent. Amongst the 31-40 ranked corporate, Akumentis has the highest growth at 29.1 per cent followed by Merck at 21.3 and Bharat Serums at 18.7 per cent.
Amongst the 41-50 ranked corporate, Allergan has the highest growth at 26.8 per cent followed by Wallace at 11.6 per cent and Apex at 11.5 per cent. Amongst the 51-60 ranked corporate, Eli Lilly grew at 34.4 per cent followed by Troikaa at 27 per cent and Centaur at 23.7 per cent.
Amongst the 61-70 ranked corporate, Boehringer grew at 61.1 per cent followed by Fresenius Kabi which grew by 53.9 per cent followed by RPG at 29.6 per cent. Glenmark entered the Rs 2000-crore mark, Natco Rs 100 crore on MAT Basis.
Amongst the top 10, Sun Pharma grew by 23.2 per cent followed by Cipla at 15.4 per cent and Ranbaxy at 14.7 per cent. 24 companies have crossed the growth of IPM for the month of May 2015 amongst top 50. Amongst the 11-20 ranked companies Glenmark has the highest growth of 28.9 per cent followed by Torrent at 27 per cent and Aristo at 21.7 per cent.
Amongst the 21-30 ranked companies, Wockhardt has the highest growth at 21.2 per cent followed by Alembic 15.1 per cent and Zuventus at 13.3 per cent.
Indian companies have grown at 11.2 per cent versus 10.2 per cent for MNCs in May 2015. Amongst the top 50 in MNCs Allergan grew by 26.8 per cent followed by MSD at 23.9 per cent and Merck at 21.3 per cent. Under the non-NLEM category, Indian companies grew at 4.7 per cent whereas MNCs grew at 6.9 per cent.
The DPCO containing molecules market grew at 5.3 per cent whereas the non DPCO market grew by 12.1 per cent and non-Sch Para 19 Market at 7.2 per cent resulting in an overall growth of 11 per cent for May 2015. NLEM and non —NLEM Category showed unit growth at -0.3 per cent and 3.4 per cent respectively. The non-Sch Para 19 market grew at 4.3 per cent from units perspective
The DPCO 2013 portfolio for Pfizer grew at 5.7 per cent, Ranbaxy 29.5 per cent, GSK at -1.2 per cent and Abbott 18.5 per cent.
From therapy perspective, eight therapies have outgrown the IPM growth. The respiratory market grew at 11.9 per cent, gastrointestinal market grew at 14.2 per cent, pain and analgesics market grew at 8.5 per cent whereas anti-infectives grew at 5.5 per cent. The anti-diabetic market grows at 20.7per cent and cardiac at 10.7 per cent in chronic business. The derma market grew by 20 per cent and urology market at 23 per cent.
From regional perspective, 12 regions have outgrown the IPM growth. The UP East market grew the highest at 24.8 per cent followed by North East market at 21.7 per cent and North AP Market at 18.2 per cent. Two regions had negative growth in May 2015.
Amoxycillin + Clavulanic acid market grew at seven per cent whereas Glimepiride + Metformin grew at 10 per cent at number two.
The markets of paracetamol grew at 1.1 per cent, Atorvastatin 5.2 per cent, Probiotic Microbes at 26.1 per cent, Cefixime 3.8 per cent, Pantoprazole 15.3 per cent, Montelukast + Levocetrizine at 23.7 per cent, Glimepiride + Metformin + Pioglitazone at 13.9 per cent, Vitamin-D at 26.3 per cent, Hydroquinone + Mometasone + Tretinoin at 4.9 per cent, Voglibose + Metformin + Glimepiride at 47.7 per cent, Rosuvastatin at 22.9 per cent, protein supplements at 16.3 per cent, Azithromycin at 9.1 per cent.
Mixtard leads the pack with Rs 32 crores followed by Augmentin at Rs 20.56 crores and Glycomet GP at Rs 24.23 crores for May 15. Glycomet – GP crosses the Rs 300 crore-mark to join with Augmentin in Rs 300-crore league. Monocef grew by 25.7 per cent followed by Lantus at 24.6 per cent, Becosules at 23.1 per cent, Corex at 21.9 per cent and augmentin at 19.9 per cent amongst the top 10 brands.
Few brands which have gained ranks include Chymoral Forte (+122), Phensedyl Cough (+93), Janumet (+79), Januvia (+68), Pentaxim (+62), Betnesol (+59), Betnovate C ( +56), Shelcal (+55), Panderm Plus (+46), Huminsulin (+36), Mox (+28), Clexane (+24), Zoryl- M (+23), Istamet (+22), Pantocid D SR (+21), Spasmo Proxyvon Plus (+19), Orofer XT, Rosuvas andLevipil (+16), Magnex & Aztor (+15), Jalra-M (+14), Mifegest Kit & Monocef O (+12), Galvus (+11), Omez and Pantodac (+10) amongst top 100 Brands over April 2014. A total of 224 brands and 377 SKUs were launched in May 2015. Top new brands for May were Zotide, Forxiga and Viroclear.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
Comments are closed.